AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - US0234361089 - Common Stock
100.99 USD
+0.01 (+0.01%)
100.99 USD
0 (0%)
Taking everything into account, AMED scores 5 out of 10 in our fundamental rating. AMED was compared to 101 industry peers in the Health Care Providers & Services industry. AMED scores excellent on profitability, but there are some minor concerns on its financial health. AMED is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AMED was profitable.
AMED had a positive operating cash flow in the past year.
Of the past 5 years AMED 4 years were profitable.
AMED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AMED (3.87%) is better than 72.12% of its industry peers.
With a decent Return On Equity value of 6.95%, AMED is doing good in the industry, outperforming 66.35% of the companies in the same industry.
AMED has a better Return On Invested Capital (10.34%) than 81.73% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMED is in line with the industry average of 9.14%.
The last Return On Invested Capital (10.34%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROIC | 10.34% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
The Profit Margin of AMED (3.56%) is better than 68.27% of its industry peers.
AMED's Profit Margin has declined in the last couple of years.
AMED's Operating Margin of 9.41% is fine compared to the rest of the industry. AMED outperforms 78.85% of its industry peers.
AMED's Operating Margin has been stable in the last couple of years.
AMED has a better Gross Margin (43.19%) than 71.15% of its industry peers.
AMED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
AMED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for AMED has been increased compared to 1 year ago.
AMED has more shares outstanding than it did 5 years ago.
AMED has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.10 indicates that AMED is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.10, AMED is doing good in the industry, outperforming 75.00% of the companies in the same industry.
AMED has a debt to FCF ratio of 1.55. This is a very positive value and a sign of high solvency as it would only need 1.55 years to pay back of all of its debts.
AMED has a Debt to FCF ratio of 1.55. This is amongst the best in the industry. AMED outperforms 85.58% of its industry peers.
AMED has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.26, AMED is in the better half of the industry, outperforming 65.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Altman-Z | 4.1 |
ROIC/WACC1.2
WACC8.61%
2.3 Liquidity
A Current Ratio of 1.36 indicates that AMED should not have too much problems paying its short term obligations.
AMED has a Current ratio (1.36) which is in line with its industry peers.
AMED has a Quick Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.36, AMED perfoms like the industry average, outperforming 50.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.24% over the past year.
Measured over the past years, AMED shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.46% on average per year.
AMED shows a small growth in Revenue. In the last year, the Revenue has grown by 4.93%.
AMED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.73% yearly.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
3.2 Future
The Earnings Per Share is expected to grow by 6.47% on average over the next years.
The Revenue is expected to grow by 4.95% on average over the next years.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.26, AMED is valued on the expensive side.
Based on the Price/Earnings ratio, AMED is valued a bit cheaper than 67.31% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.17, AMED is valued a bit cheaper.
A Price/Forward Earnings ratio of 19.15 indicates a rather expensive valuation of AMED.
Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than 62.50% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMED to the average of the S&P500 Index (22.78), we can say AMED is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 65.38% of the companies listed in the same industry.
AMED's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AMED is cheaper than 78.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.18 | ||
| EV/EBITDA | 11.63 |
4.3 Compensation for Growth
AMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
100.99
+0.01 (+0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.54%
Inst Owner Change2.85%
Ins Owners1.88%
Ins Owner Change-35.13%
Market Cap3.32B
Analysts54.12
Price Target102.87 (1.86%)
Short Float %9.94%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.78%
Min EPS beat(2)12.12%
Max EPS beat(2)13.43%
EPS beat(4)2
Avg EPS beat(4)-0.15%
Min EPS beat(4)-15.99%
Max EPS beat(4)13.43%
EPS beat(8)3
Avg EPS beat(8)-1.75%
EPS beat(12)6
Avg EPS beat(12)2.15%
EPS beat(16)9
Avg EPS beat(16)3.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-1.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.17%
Revenue beat(16)2
Avg Revenue beat(16)-2.65%
PT rev (1m)0%
PT rev (3m)0.02%
EPS NQ rev (1m)7.75%
EPS NQ rev (3m)3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0.63%
Revenue NQ rev (3m)-0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 | ||
| P/S | 1.38 | ||
| P/FCF | 14.18 | ||
| P/OCF | 13.87 | ||
| P/B | 2.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.63 |
EPS(TTM)4.75
EY4.7%
EPS(NY)5.27
Fwd EY5.22%
FCF(TTM)7.12
FCFY7.05%
OCF(TTM)7.28
OCFY7.21%
SpS73.04
BVpS37.47
TBVpS-1.84
PEG (NY)1.61
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROCE | 13.09% | ||
| ROIC | 10.34% | ||
| ROICexc | 12.85% | ||
| ROICexgc | 184.87% | ||
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% | ||
| FCFM | 9.75% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score6
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Debt/EBITDA | 1.13 | ||
| Cap/Depr | 8.5% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 8.42 | ||
| Cash Conversion | 83.2% | ||
| Profit Quality | 273.49% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z | 4.1 |
F-Score6
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y8.08%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year19.91%
EBIT Next 3Y9.46%
EBIT Next 5YN/A
FCF growth 1Y132.55%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y110.02%
OCF growth 3Y5.48%
OCF growth 5Y1.88%